This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
‘Significant Potential’: This ASX Stock Is Winning The Race To Make Cancer Care Heart-Safe
- Leading cardiologist says bisantrene has potential to significantly change cancer treatment landscape
- Bisantrene could minimise damage to the heart linked to many cancer therapies
- New CEO is prioritising swift delivery of bisantrene to patients and maximising shareholder returns
For all the excitement about curing cancer or the disease going into remission, the relief for some patients can often be short-lived if the treatment leaves them with other potentially long-term health repercussions.
Cardiovascular health problems are typically the most common, but Race Oncology (ASX:RAC) is working to minimise damage to the heart linked to almost all cancer therapies with its core asset bisantrene. Read more here.